|
|
|
|
|
by dalke
3621 days ago
|
|
If you think my comments are "destructive criticism" then I invite you to post to a medchemist's site, like Derek Lowe's, or present at a medchemist's conference and see the responses you get. By giving you all these pointers I am trying to provide the "constructive criticism" you say you want. I am also trying to establish my bona fides, so you might have a chance of accepting as true my statement that you've offered no insights which were not already known a century ago. It's not like the concepts underlying unit testing didn't exist before CS developed them. And I have no wish to put up with an eternal September here on HN when some enthusiastic engineer thinks the methods from that field can be moved over to drug development. It very similar to what Lowe, above, calls the 'Andy Grove fallacy' - http://blogs.sciencemag.org/pipeline/archives/2015/04/02/sil... . Also, there's an entire field for the theory of the design of experiments: https://en.wikipedia.org/wiki/Design_of_experiments . These are used in drug development. Perhaps it's software development which should incorporate ideas drug development, and not the other way around. |
|
You know better than me. You're right, I can offer no new insights, only the knowledge gained from experience (not necessarily theory). And from my experience what makes a product work is not the algorithms used, or the number of people working on it, or the technology used - it is how its progress is maintained via automated/constant testing.
If you think that the resources spent on maintaining progress in the drug development world are suitable - that's good to know.